INOVIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Inovio Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. for alleged misleading statements and failure to disclose critical information regarding its CELLECTRA device and the INO-3107 Biologics License Application [2][5]. Allegation Details - The lawsuit claims that during the Class Period, Inovio made false statements about the manufacturing quality of its CELLECTRA device, which impacted the likelihood of submitting the INO-3107 BLA to the FDA by the second half of 2024 [5]. - It is alleged that Inovio lacked sufficient information to support the eligibility of the INO-3107 BLA for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [5]. - The lawsuit asserts that when the true information became public, investors suffered financial damages, particularly after the FDA's announcement regarding the BLA's acceptance on a standard review timeline rather than accelerated approval [5]. Stock Price Impact - Following the FDA's announcement on December 29, 2025, Inovio's stock price dropped by $0.56 per share, representing a decline of 24.45%, closing at $1.73 per share [5].